(ALHC) Alignment Healthcare - Overview
Sector: Healthcare | Industry: Healthcare Plans | Exchange: NASDAQ (USA) | Market Cap: 3.380m USD | Total Return: 10.8% in 12m
Avg Turnover: 89.0M
Qual. Beats: 5
Rev. Trend: 99.8%
Qual. Beats: 1
Warnings
P/E ratio 163.5
Altman Z'' -0.80 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Alignment Healthcare, Inc. (ALHC) operates a consumer-centric healthcare platform specifically designed for the senior population in the United States. Founded in 2013 and headquartered in Orange, California, the company provides various Medicare Advantage plans tailored to individual member needs.
The business model relies on a value-based care framework, which incentivizes providers to prioritize patient outcomes and cost efficiencies over the volume of services rendered. This sector is characterized by high regulatory oversight, as Medicare Advantage plans are funded through federal contracts with the Centers for Medicare & Medicaid Services (CMS).
Investors can further evaluate these operational metrics and sector trends by reviewing the data available on ValueRay.
- Medicare Advantage membership growth drives top-line revenue expansion
- MLR fluctuations impact profitability amid rising senior utilization rates
- CMS Star Ratings performance dictates critical federal bonus payments
- Geographical expansion into new markets increases operational capital expenditure
- Regulatory shifts in Medicare reimbursement levels influence net margins
| Net Income: 19.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 16.63 > 1.0 |
| NWC/Revenue: 11.50% < 20% (prev 10.57%; Δ 0.92% < -1%) |
| CFO/TA 0.20 > 3% & CFO 252.0m > Net Income 19.8m |
| Net Debt (-1.07b) to EBITDA (66.4m): -16.18 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (213.1m) vs 12m ago 10.08% < -2% |
| Gross Margin: 12.38% > 18% (prev 0.12%; Δ 1.23k% > 0.5%) |
| Asset Turnover: 394.7% > 50% (prev 335.2%; Δ 59.50% > 0%) |
| Interest Coverage Ratio: 2.25 > 6 (EBITDA TTM 66.4m / Interest Expense TTM 15.9m) |
| A: 0.39 (Total Current Assets 1.15b - Total Current Liabilities 656.0m) / Total Assets 1.26b |
| B: -0.79 (Retained Earnings -997.6m / Total Assets 1.26b) |
| C: 0.03 (EBIT TTM 35.7m / Avg Total Assets 1.08b) |
| D: -0.95 (Book Value of Equity -997.4m / Total Liabilities 1.05b) |
| Altman-Z'' = -0.80 = CCC |
| DSRI: 0.91 (Receivables 277.7m/214.1m, Revenue 4.26b/3.00b) |
| GMI: 0.93 (GM 12.38% / 11.57%) |
| AQI: 0.72 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.42 (Revenue 4.26b / 3.00b) |
| TATA: -0.18 (NI 19.8m - CFO 252.0m) / TA 1.26b) |
| Beneish M = -3.21 (Cap -4..+1) = AA |
As of May 26, 2026, the stock is trading at USD 16.35 with a total of 2,717,480 shares traded.
Over the past week, the price has changed by +3.94%,
over one month by -22.62%,
over three months by -16.58% and
over the past year by +10.77%.
Alignment Healthcare has received a consensus analysts rating of 4.09. Therefore, it is recommended to buy ALHC.
- StrongBuy: 6
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 25.2 | 53.8% |
P/E Trailing = 163.5
P/E Forward = 204.0816
P/S = 0.794
P/B = 16.3281
Revenue TTM = 4.26b USD
EBIT TTM = 35.7m USD
EBITDA TTM = 66.4m USD
Long Term Debt = 323.6m USD (from longTermDebt, last quarter)
Short Term Debt = 1.96m USD (from shortTermDebt, last fiscal year)
Debt = 336.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.35m
Net Debt = -1.07b USD (calculated: Debt 336.3m - CCE 1.41b)
Enterprise Value = 2.31b USD (3.38b + Debt 336.3m - CCE 1.41b)
Interest Coverage Ratio = 2.25 (Ebit TTM 35.7m / Interest Expense TTM 15.9m)
EV/FCF = 9.74x (Enterprise Value 2.31b / FCF TTM 236.6m)
FCF Yield = 10.26% (FCF TTM 236.6m / Enterprise Value 2.31b)
FCF Margin = 5.56% (FCF TTM 236.6m / Revenue TTM 4.26b)
Net Margin = 0.47% (Net Income TTM 19.8m / Revenue TTM 4.26b)
Gross Margin = 12.38% ((Revenue TTM 4.26b - Cost of Revenue TTM 3.73b) / Revenue TTM)
Gross Margin QoQ = 11.70% (prev 12.18%)
Tobins Q-Ratio = 1.83 (Enterprise Value 2.31b / Total Assets 1.26b)
Interest Expense / Debt = 4.73% (Interest Expense 15.9m / Debt 336.3m)
Taxrate = 0.22% (25.0k / 11.4m)
NOPAT = 35.6m (EBIT 35.7m * (1 - 0.22%))
Current Ratio = 1.75 (Total Current Assets 1.15b / Total Current Liabilities 656.0m)
Debt / Equity = 1.63 (Debt 336.3m / totalStockholderEquity, last quarter 206.9m)
Debt / EBITDA = -16.18 (Net Debt -1.07b / EBITDA 66.4m)
Debt / FCF = -4.54 (Net Debt -1.07b / FCF TTM 236.6m)
Total Stockholder Equity = 172.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.84% (Net Income 19.8m / Total Assets 1.26b)
RoE = 1.69% (Net Income TTM 19.8m / Total Stockholder Equity 1.17b)
RoCE = 2.39% (EBIT 35.7m / Capital Employed (Equity 1.17b + L.T.Debt 323.6m))
RoIC = 6.83% (NOPAT 35.6m / Invested Capital 521.7m)
WACC = 6.00% (E(3.38b)/V(3.72b) * Re(6.13%) + D(336.3m)/V(3.72b) * Rd(4.73%) * (1-Tc(0.00)))
Discount Rate = 6.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 5.65%
[DCF] Terminal Value 77.97% ; FCFF base≈149.6m ; Y1≈171.5m ; Y5≈252.4m
[DCF] Fair Price = 23.57 (EV 3.80b - Net Debt -1.07b = Equity 4.87b / Shares 206.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.42 | # QB: 5
Revenue Correlation: 99.84 | Revenue CAGR: 44.70% | SUE: 1.13 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.20 | Chg30d=+1.25% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.14 | Chg30d=-3.57% | Revisions=-33% | Analysts=4
EPS current Year (2026-12-31): EPS=0.47 | Chg30d=+8.57% | Revisions=+14% | GrowthEPS=+47.8% | GrowthRev=+31.3%
EPS next Year (2027-12-31): EPS=0.72 | Chg30d=+2.48% | Revisions=+33% | GrowthEPS=+52.1% | GrowthRev=+25.5%
[Analyst] Revisions Ratio: -33%